Medicare-certified hospice and palliative care agencies with strong census, clean compliance records, and diversified referral networks typically sell for 4x–7x EBITDA. Here is what drives value — and what destroys it — in today's hospice M&A market.
Find Hospice & Palliative Care Businesses For SaleHospice and palliative care agencies are primarily valued on a multiple of adjusted EBITDA, with buyers scrutinizing Medicare reimbursement history, average daily census trends, and compliance records as closely as financial statements. Unlike many lower middle market businesses, hospice valuations are heavily influenced by regulatory factors — including Medicare cap exposure, survey deficiency history, and OIG audit risk — that can significantly compress or expand the multiple a qualified buyer will pay. Agencies with $300K–$1.5M in normalized EBITDA, clean CMS survey histories, and stable clinical leadership command the strongest valuations in a market dominated by private equity-backed roll-up platforms and regional strategic acquirers.
4×
Low EBITDA Multiple
5.5×
Mid EBITDA Multiple
7×
High EBITDA Multiple
Hospice agencies at the low end of the range (4x–4.5x EBITDA) typically exhibit one or more risk factors: approaching the Medicare annual cap limit, high reliance on a single referral source, elevated staff turnover, or incomplete financial documentation. Mid-range multiples (5x–6x) reflect agencies with stable ADC, diversified referrals, and clean compliance records but limited geographic scale or accreditation. Premium multiples (6.5x–7x and above) are reserved for Medicare-certified agencies with growing census, ACHC or CHAP accreditation, tenured clinical leadership, no active CMS investigations, and strong operational infrastructure that supports a buyer's platform integration thesis.
$2.8M
Revenue
$700K (normalized, post-owner compensation adjustment)
EBITDA
5.5x
Multiple
$3.85M
Price
Asset purchase with Medicare provider agreement novation; $3.1M cash at closing funded via SBA 7(a) loan; $385K seller note (10%) at 6.5% interest over 5 years tied to ADC retention above 65 patients for 12 months post-close; $350K compliance escrow released at 18 months contingent on no CMS recoupment demands or survey deficiencies
EBITDA Multiple (Primary Method)
The dominant valuation approach in hospice M&A. Buyers calculate adjusted EBITDA by normalizing owner compensation, related-party rent or management fees, personal expenses run through the business, and one-time costs, then apply a multiple based on operational quality, compliance history, and census stability. For a hospice with $1.5M in normalized EBITDA and strong fundamentals, a 6x multiple produces a $9M enterprise value.
Best for: All hospice agency transactions in the lower middle market where the buyer is a PE-backed platform, regional operator, or SBA-financed owner-operator
Revenue Multiple
Some buyers use a revenue multiple as a secondary sanity check, particularly when EBITDA margins are compressed or owner compensation is difficult to normalize. Hospice agencies typically trade at 0.8x–1.5x trailing twelve-month revenue, with higher margins and clean Medicare records pushing toward the upper end. This method is less reliable than EBITDA multiples and is rarely used as the primary pricing mechanism by sophisticated acquirers.
Best for: Preliminary valuation screening or situations where EBITDA is temporarily depressed due to one-time expenses or owner transition costs
Average Daily Census (ADC) Per-Patient Valuation
Experienced hospice acquirers often cross-reference valuation using a per-patient or per-ADC metric, typically ranging from $8,000–$20,000 per patient in the current census depending on payer mix, geography, and clinical complexity. An agency with an ADC of 80 patients might be benchmarked at $640K–$1.6M in implied value per this method, which is then triangulated against the EBITDA multiple approach. This metric reflects the embedded revenue stream each certified patient represents under the Medicare per diem reimbursement model.
Best for: Buy-side underwriting and deal benchmarking by strategic acquirers and PE platforms with existing hospice operations
Consistent or Growing Average Daily Census (ADC)
ADC is the heartbeat of a hospice business. Buyers want to see stable or growing patient census over at least 24 months, with length-of-stay trends that reflect appropriate clinical eligibility — typically 60–120+ average days. An ADC of 40–150 patients is the sweet spot for lower middle market transactions. Agencies that can demonstrate organic ADC growth without over-reliance on a single referral channel command meaningfully higher multiples.
Diversified Referral Network With No Single-Source Dependency
A hospice that draws admissions from multiple hospitals, skilled nursing facilities, assisted living communities, and independent physician practices is far more defensible than one receiving 40% of its referrals from a single SNF or hospitalist group. Buyers target agencies where no single referral source exceeds 20% of admissions, and they will pay a premium for documented, multi-year relationships supported by anti-kickback compliant agreements.
Clean Medicare Survey History and No Active CMS Investigations
CMS survey results are among the first documents a buyer's due diligence team requests. An agency with no condition-level deficiencies, no active OIG investigations, and no unresolved Medicare overpayment demands is significantly more attractive — and less risky — than one with compliance flags. A clean survey history also reduces the likelihood of a buyer requiring a large compliance escrow holdback at closing.
Tenured Clinical Leadership Willing to Stay Post-Sale
The Director of Nursing and Administrator are the operational backbone of any hospice agency. Buyers price in significant execution risk when these individuals plan to leave at closing. Agencies where key clinical leaders — including IDT members such as social workers and chaplains — are willing to sign retention agreements or employment contracts with the acquirer are valued materially higher and close with fewer contingencies.
ACHC or CHAP Accreditation and Strong QAPI Infrastructure
Third-party accreditation from ACHC or CHAP signals to buyers that the agency has invested in clinical quality systems and is prepared for rigorous regulatory scrutiny. Combined with well-documented QAPI meeting minutes, IDT notes, and outcome tracking, accreditation reduces perceived compliance risk and supports a higher multiple — particularly for PE-backed buyers with institutional lenders who require quality benchmarks.
Favorable Medicare Cap Position
Hospices operating well below the Medicare annual aggregate cap limit have greater revenue headroom and pose lower compliance risk. Buyers calculate cap exposure as part of every deal and will discount valuation or require escrow holdbacks when an agency is operating above 90% of its cap. Agencies comfortably below the cap threshold are priced more aggressively by competing buyers.
Active Medicare Overpayment Demands, RAC Audit Findings, or OIG Investigations
Nothing stops a hospice deal faster — or compresses a valuation more severely — than unresolved Medicare compliance exposure. Active RAC audit recoupment demands, OIG investigations, or a history of billing for ineligible patients creates significant liability that buyers either price into a lower offer, structure into a large escrow holdback, or walk away from entirely. Sellers must disclose and ideally resolve these issues before going to market.
Approaching or Exceeding the Medicare Annual Cap Limit
The Medicare hospice annual aggregate cap limits per-patient reimbursement and creates significant overpayment liability when exceeded. Agencies operating near or above the cap signal potential eligibility problems — patients admitted who did not meet the six-month terminal prognosis standard — and may face mandatory repayment to CMS. Buyers will heavily discount or restructure deals around this exposure, often requiring seller-financed notes contingent on cap resolution.
Revenue Concentration in a Single Referral Source or Geography
An agency that depends on one hospital system, one SNF, or one physician group for the majority of its admissions is fragile by definition. If that relationship deteriorates post-acquisition — due to a change in facility ownership, a competing hospice relationship, or a compliance dispute — the acquirer's census collapses. Buyers model this concentration risk directly into their offer price and deal structure.
High Clinical Staff Turnover or Over-Reliance on Contract Labor
Hospice care is inherently relationship-driven, and high RN or social worker turnover disrupts patient and family trust while driving up per-visit labor costs. Agencies staffed heavily with contracted rather than employed clinicians raise questions about care consistency and profitability. Buyers will scrutinize turnover rates, W-2 versus 1099 ratios, and open position counts as key indicators of operational health during due diligence.
Incomplete Financial Records or Commingled Personal Expenses
Many founder-operated hospice agencies have informal financial practices — personal vehicle expenses, family payroll, real estate transactions, or insurance premiums running through the business without documentation. This makes EBITDA normalization difficult, raises lender red flags in SBA transactions, and can cause buyer distrust that derails or discounts a deal. Sellers should invest in 2–3 years of clean, accrual-based financials and a formal EBITDA normalization schedule before going to market.
Find Hospice & Palliative Care Businesses For Sale
Signal-scored targets with seller motivation, multiples, and outreach — free to join.
Medicare-certified hospice agencies with $1M–$5M in revenue typically sell for 4x–7x normalized EBITDA. The specific multiple depends on census stability, compliance history, referral diversification, and clinical leadership quality. Agencies with clean CMS survey records, ADC growth, and no Medicare cap exposure tend to achieve 6x–7x multiples, while those with compliance risks, concentration issues, or incomplete financials often land in the 4x–5x range.
Medicare cap exposure is one of the most significant valuation risk factors in a hospice sale. Agencies operating above 90% of their annual aggregate cap limit face potential mandatory repayment to CMS and signal eligibility documentation concerns to buyers. This typically results in a lower purchase price, a larger escrow holdback at closing, or a seller note structured to absorb potential recoupment. Agencies comfortably below the cap — generally below 75% utilization — attract more aggressive offers and cleaner deal structures.
Yes. Hospice agency acquisitions are SBA-eligible, and the SBA 7(a) loan program is commonly used by owner-operator buyers to finance acquisitions in the $1M–$5M range. Lenders will require 3 years of business tax returns, normalized EBITDA documentation, a business appraisal, and evidence of Medicare certification in good standing. Compliance exposure, active audits, or unresolved CMS investigations can disqualify a deal from SBA financing, which is why resolving these issues before going to market is critical.
Hospice Medicare certifications are non-transferable in an asset sale and require a formal Change of Ownership (CHOW) process with CMS. The buyer must submit a CHOW application, obtain state licensure, and — in most states — have the provider agreement novated to the new owner. This process can take 60–120 days and requires careful coordination with your healthcare attorney and the buyer. In a stock sale, the existing Medicare certification may transfer with the entity, but buyers typically require escrow holdbacks to protect against pre-closing compliance liabilities.
The single highest-impact action a hospice seller can take is presenting 3 years of clean, accrual-based financial statements with a well-documented EBITDA normalization schedule. Beyond financials, demonstrating a growing ADC, a diversified referral network with no single-source dependency, a clean CMS survey history, and a stable clinical leadership team that is willing to stay post-sale will directly increase your valuation multiple and reduce the likelihood of buyers requiring large escrow holdbacks or earnouts at closing.
Most hospice agency sales in the lower middle market take 12–24 months from the decision to sell through closing. The timeline includes 2–4 months of financial and operational preparation, 2–4 months of marketing and buyer qualification, 3–6 months of due diligence and deal structuring, and 2–4 months for the Medicare CHOW process, state licensure transfer, and legal documentation. Agencies with unresolved compliance issues, incomplete records, or complex ownership structures typically take longer.
Most PE-backed acquirers and strategic buyers are highly motivated to retain clinical staff — particularly the Director of Nursing, Administrator, and core IDT members — because census continuity depends on it. Many buyers will offer employment agreements, retention bonuses, or equity participation to key clinical leaders as part of the acquisition. That said, sellers should have candid conversations with their teams early enough to surface retention risks and address them before they become deal-breaking issues in due diligence.
More Hospice & Palliative Care Guides
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers